This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Doherty, T. M. Articles by Weintraub, N. L. Search for Related Content PubMed PubMed Citation Articles by Doherty, T. M. Articles by Weintraub, N. L.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:e38.)
© 2005 American Heart Association, Inc.

Letters to the Editor

Lipopolysaccharide, Toll-Like Receptors, and the Immune Contribution to Atherosclerosis

Terence M. Doherty; Prediman K. Shah

Division of Cardiology and the Atherosclerosis Research Center, Burns and Allen Research Institute, Cedars-Sinai Medical Center, and David Geffen School of Medicine at University of California, Los Angeles

Moshe Arditi

Division of Infectious Diseases and Immunology and the Atherosclerosis Research Center, Burns and Allen Research Institute, Cedars-Sinai Medical Center, and David Geffen School of Medicine at University of California, Los Angeles

An extract of the first 250 words of the full text is provided, because this article has no abstract.

To the Editor:

Stoll and colleagues present an intriguing and timely review on the potential contribution of lipopolysaccharide (LPS) to development of atherosclerotic plaque.¹ Recent studies have now provided important new insights into how LPS and other pathogen-associated molecular patterns (PAMPs) might directly contribute to atherosclerosis and suggest that the contribution of immune mechanisms to atherogenesis may be more important that presently realized. Walton et al reported that modified but not native low-density lipoproteins (LDL) upregulate TLR4 in endothelial cells, are recognized by TLR4 in a CD14-independent fashion, and cause increased endothelial cell expression of IL-8.² Studies from Witztum’s laboratory indicate that modified LDL signals mediated by TLR4 cause actin polymerization and spreading of macrophages that results in decreased phagocytosis of apoptotic cells and enhanced uptake of modified LDL.³

Recent in vivo studies provide more direct insights in the role of TLR signaling events in atherosclerosis. Bjorkbacka et al reported that genetic deficiency of CD14 in apolipoprotein E (apoE)-null mice had no effect on early lesion development.⁴ Because CD14 seems to be important for LPS-induced TLR4 signaling, this might at first imply that TLR4 signaling is not involved in atherosclerosis. However, results from our laboratory showed that TLR4–/–apoE–/– mice demonstrated reduced atherosclerosis.⁵ These findings collectively are most consistent with the interpretation that TLR4 signaling contributes to atherosclerosis, and either LPS is not the ligand, CD14 is not essential to transduce LPS signals through TLR4, or some other ligand is interacting with TLR4 in a CD14-independent manner to influence plaque development. . . . [Full Text of this Article]

Lynn L. Stoll

Department of Internal Medicine, Division of Cardiovascular Diseases, University of Iowa and the VA Medical Center, Iowa City

Gerene M. Denning

Department of Internal Medicine, Division of Infectious Diseases, University of Iowa and the VA Medical Center, Iowa City

Neal L. Weintraub

Department of Internal Medicine, Division of Cardiovascular Diseases, University of Iowa and the VA Medical Center, Iowa City